antibodi
constitut
rapidli
grow
class
human
therapeut
second
largest
class
drug
vaccin
grow
number
antibodi
enter
clinic
trial
human
deriv
phagedisplay
technolog
transgen
mice
express
human
immmunoglobulin
gene
howev
best
mab
clinic
applic
deriv
natur
human
antibodi
gener
result
vivo
immun
respons
product
human
anim
repertoir
ii
human
origin
thu
minim
risk
reactiv
selfantigen
lastli
iii
passiv
immunotherapi
human
igg
confer
immedi
protect
without
side
effect
link
use
chimer
human
mab
contain
animalderiv
amino
acid
sequenc
furthermor
consider
evid
indic
antibodi
repres
new
although
histor
valid
approach
develop
therapi
bacteri
viral
pathogen
caus
diseas
individu
impair
immun
respons
andor
avail
drug
ebv
long
use
immort
human
blymphocyt
vitro
isol
human
mab
method
routin
embrac
due
poor
effici
result
transform
cell
frequent
unstabl
fail
grow
secret
igg
agonist
toll
receptor
eg
cpg
odn
synthet
oligodeoxynucleotid
contain
immunostimulatori
deoxycytidyldeoxyguanosin
motif
report
improv
ebv
infect
clone
effici
howev
clear
consensu
best
condit
use
subset
blymphocyt
use
appli
ebv
immort
procedur
presenc
differ
amount
cpg
without
healthi
donor
select
basi
high
titer
cmvspecif
igg
blood
obtain
immort
effici
compar
recent
report
therefor
reevalu
step
crucial
cell
immort
establish
optim
procedur
isol
human
mab
repertoir
immun
donor
result
method
highli
reproduc
effect
rapid
valid
success
isol
clone
human
blymphocyt
secret
high
level
igg
bind
neutral
human
cytomegaloviru
hcmv
hcmv
ubiquit
opportunist
viru
infect
adult
human
popul
persist
life
human
host
primari
infect
hcmv
infect
immunocompet
individu
gener
result
subclin
diseas
contrast
hcmv
infect
immunocompromis
individu
may
caus
lethal
infect
inde
hcmv
remain
singl
import
pathogen
hematopoiet
stem
cell
transplant
well
organ
transplant
effect
neutral
mab
would
make
major
contribut
elimin
hcmv
patient
isol
fulli
human
mab
gener
natur
human
immun
respons
like
identifi
effect
therapeut
antibodi
mani
approach
use
gener
human
mab
howev
effici
reproduc
process
isol
human
mab
desir
specif
natur
repertoir
avail
agonist
report
improv
ebv
infect
clone
effici
howev
known
agonist
cpg
odn
protect
wide
rang
viral
pathogen
mind
reason
presenc
cpg
ebv
infect
might
exert
neg
effect
decid
separ
activ
ebv
infect
two
sequenti
phase
develop
technolog
rais
human
mab
clinic
applic
base
two
discret
step
sequenti
figur
first
purifi
human
blymphocyt
treat
next
addit
remov
activ
cell
infect
ebv
distinct
step
new
process
compar
method
use
presenc
ebv
combin
method
use
ebv
alon
basic
figur
differ
experiment
set
compar
pool
cell
deriv
healthi
donor
minim
donor
variabl
result
clearli
demonstr
activ
blymphocyt
ebv
exposur
lead
improv
immort
highlight
viabil
cell
follow
ebv
transform
significantli
higher
obtain
combin
basic
condit
figur
shortterm
viabil
b
lymphocyt
immort
follow
basic
procedur
higher
b
lymphocyt
treat
combin
procedur
attribut
polyclon
activ
elicit
ebv
parallel
effici
immort
inde
well
document
exposur
human
blymphocyt
ebv
result
cell
death
proport
cell
blymphocyt
activ
immedi
immort
follow
exposur
ebv
remov
activ
agent
immort
significantli
improv
growth
viabil
blymphocyt
allow
higher
proport
cell
immort
inde
stimul
ebv
infect
perform
separ
rather
simultan
stimul
cell
exhibit
increas
prolifer
potenti
improv
viabil
contrast
combin
presenc
activ
agent
ebv
advers
effect
cell
viabil
ebv
infect
figur
b
neg
effect
combin
method
viabil
surpris
given
induc
robust
polyclon
activ
prolifer
blymphocyt
effect
significantli
enhanc
report
trigger
result
higher
transform
rate
b
cell
infect
ebv
comparison
ebv
transform
presenc
ebv
sequenti
exposur
b
cell
separ
ebv
investig
result
obtain
use
differ
experiment
set
cell
popul
clearli
demonstr
use
combin
ebv
exert
neg
effect
cell
transform
conceiv
detriment
effect
relat
antiprolif
activ
antivir
cytokin
induc
inde
signific
level
express
rest
blymphocyt
upregul
increas
express
correl
increas
respons
ligand
indic
posit
feedback
loop
enhanc
effect
kinet
studi
demonstr
optim
concentr
combin
provid
maxim
cell
stimul
day
data
shown
observ
line
cellcycl
analys
demonstr
time
frame
b
cell
enter
cell
cycl
independ
memori
phenotyp
sequenti
method
modifi
express
receptor
ebv
next
step
correl
effici
ebv
infect
express
directli
upregul
one
earliest
marker
express
ebvinfect
blymphocyt
express
high
level
ebvtransform
b
cell
express
correl
igg
secret
result
demonstr
express
number
posit
cell
mean
fluoresc
intens
higher
cell
expos
polyclon
activ
ebv
separ
expos
simultan
figur
blymphocyt
repres
whole
repertoir
select
donor
immort
sequenti
method
show
significantli
higher
viabil
obtain
combin
method
consequ
easili
clonabl
limit
dilut
either
presenc
absenc
polyclon
activ
express
increas
ebv
infect
thu
bona
fide
addit
clone
phase
enhanc
cell
growth
howev
observ
clone
effici
may
independ
donor
suggest
also
depend
genet
background
physiolog
state
donor
issu
warrant
investig
presenc
clone
phase
may
also
practic
relev
screen
procedur
instanc
trace
amount
complet
block
hcmv
infect
vitro
hamper
screen
function
assay
moreov
potent
induc
cytokin
potenti
interf
number
bioassay
valid
sequenti
method
evalu
use
project
produc
neutral
human
mab
hcmv
lead
caus
morbid
mortal
immunocompromis
individu
seriou
pathogenet
agent
transplant
patient
absenc
therapi
vaccin
patient
treat
antivir
often
associ
consider
side
effect
emerg
drugresist
strain
hcmv
also
lead
viral
caus
congenit
infect
associ
signific
birth
defect
neurolog
damag
effect
therapi
avail
birth
hyperimmun
globulin
specif
hcmv
benefici
condit
prevent
treatment
infect
transfer
memori
b
cell
immun
anim
sever
immunodefici
recipi
confer
longterm
protect
lethal
murin
cmv
infect
indic
humor
immun
respons
effect
cmv
infect
absenc
cellmedi
respons
natur
human
mab
stronger
neutral
activ
current
avail
immunoglobulin
prepar
may
decis
altern
prevent
primari
reactiv
hcmv
infect
immunosuppress
patient
highrisk
pregnanc
use
sequenti
method
obtain
natur
antibodi
neutral
hcmv
infect
immort
blymphocyt
healthi
donor
patient
recov
acut
hcmv
infect
high
titer
antihcmvspecif
igg
coupl
virusneutr
activ
sera
criteria
select
two
donor
larger
panel
tabl
immort
blymphocyt
clone
limit
dilut
week
cluster
cell
grow
well
appreci
igg
concentr
clone
supernat
cell
determin
mean
immunoenzymat
method
measur
igg
concentr
media
normal
cell
densiti
clone
produc
hcmvspecif
igg
identifi
differ
primari
screen
assay
first
experi
total
clone
test
either
bind
specif
hcmv
envelop
glycoprotein
domain
gb
gh
shown
induc
neutral
antibodi
abil
neutral
hcmv
infect
vitro
effect
hcmv
infect
determin
hcmv
microneutr
assay
base
evalu
abil
clone
supernat
interfer
infect
hcmv
strain
laboratori
strain
atcc
cod
human
embryo
lung
fibroblast
helf
strategi
yield
clone
produc
mab
specif
gb
gh
nine
display
neutral
activ
supernat
neg
gb
gh
elisa
neutral
assay
also
screen
elisa
detect
human
igg
bind
hcmv
virion
protein
extract
beiacmv
sampl
select
screen
assay
second
experi
immort
blymphocyt
clone
limit
dilut
week
clone
screen
directli
neutral
activ
produc
igg
neutral
activ
among
well
found
bind
gb
remain
bind
either
gb
gh
domain
four
clone
chosen
promis
candid
futur
clinic
applic
basi
intrins
characterist
show
strong
bind
gb
glycoprotein
gh
glycoprotein
strongest
neutral
activ
clone
expand
absenc
feeder
layer
character
prove
specif
hcmv
envelop
glycoprotein
gb
mab
hcmv
envelop
glycoprotein
gh
mab
recogn
viral
antigen
yet
character
infer
reactiv
hcmv
virion
protein
extract
tabl
antibodi
neutral
infect
hcmv
laboratori
strain
human
helf
well
clinic
isol
human
umbil
vein
endotheli
cell
huvec
indic
neither
strain
cellspecif
lastli
none
antibodi
bound
helf
huvec
data
shown
specif
hcmv
neutral
activ
confirm
lack
signific
neutral
herp
simplex
viru
hsv
vero
cell
data
shown
clone
stabil
test
maintain
cell
month
serumfre
medium
without
addit
mab
recov
supernat
concentr
purifi
igg
maintain
neutral
activ
mab
demonstr
potent
neutral
capac
calcul
inhibitori
concentr
helf
fig
huvec
fig
potenc
hcmv
strain
fold
higher
refer
antihcmv
igg
current
use
transplant
recipi
inhibitori
activ
mab
whole
viral
replic
cycl
confirm
plaqu
reduct
neutral
assay
figur
mechan
viru
neutral
subject
ongo
studi
broad
robust
neutral
activ
mab
encourag
us
gener
recombin
igg
suitabl
prophylact
therapeut
tool
clinic
applic
aim
cell
submit
race
pcr
amplif
pcr
product
two
amplif
reaction
clone
use
eco
ri
restrict
site
sequenc
vector
use
transform
e
coli
singl
vh
vl
sequenc
obtain
cell
cultur
confirm
origin
cultur
clonal
figur
sequenc
encod
vh
vl
region
mab
clone
express
vector
express
mab
variabl
region
recombin
recombin
mab
confirm
neutral
activ
natur
mab
figur
sequenti
method
also
effect
use
frozen
cell
inde
possibl
select
antibodi
neutral
infect
frozen
pbmc
hsv
hiv
coinfect
individu
shown
summari
studi
provid
proof
concept
goodqual
fulli
human
mab
desir
specif
biolog
activ
gener
sequenti
method
strength
approach
allow
select
human
monoclon
igg
varieti
antigen
small
sampl
fresh
frozen
peripher
blood
ii
rapid
iii
screen
perform
use
varieti
assay
includ
function
assay
iv
mab
interest
easili
produc
origin
clone
recombin
protein
suitabl
clinic
applic
v
gener
iggsecret
polyclon
popul
consid
librari
antibodysecret
cell
use
select
mab
specif
consid
cell
immort
technolog
describ
proven
reproduc
effici
rapid
previous
report
techniqu
adopt
low
overal
cost
cell
biolog
laboratori
develop
fulli
human
mab
immunotherapeut
use
appli
isol
natur
mab
individu
affect
varieti
diseas
rang
infecti
diseas
cancer
autoimmun
diseas
allow
isol
larg
repertoir
human
mab
desir
specif
select
small
ml
volum
peripher
blood
use
either
fresh
frozen
blymphocyt
moreov
direct
clone
limit
dilut
robust
igg
product
allow
gener
panel
mab
differ
specif
thu
allow
develop
mab
cocktail
immunotherapi
inform
consent
obtain
peripher
blood
ml
collect
healthi
blood
donor
infecti
diseas
patient
serum
screen
reactiv
hcmv
glycoprotein
hcmv
neutral
activ
peripher
blood
mononuclear
cell
pbmc
purifi
heparin
peripher
blood
densiti
gradient
centrifug
ficollhypaqu
amersham
pharmacia
milan
itali
lymphocyt
purifi
magnet
select
miltenyi
biotec
bologna
itali
pbmc
pool
healthi
donor
divid
three
aliquot
expos
differ
ebvbas
method
immort
basic
process
lymphocyt
isol
deplet
igm
cell
highperform
cell
sorter
dakocytom
glostrup
denmark
cultur
well
plate
iscov
modifi
dulbecco
medium
imdm
supplement
lglutamin
streptomycin
uml
penicillin
nonessenti
amino
acid
fb
complet
medium
h
presenc
ebvcontain
supernat
marmoset
lymphoma
cell
atcc
washington
dc
cat
vv
cell
wash
cultur
day
complet
medium
presenc
irradi
gy
allogen
pbmc
combin
process
lymphocyt
select
mention
cultur
complet
medium
ebvcontain
supernat
vv
cpg
metabion
planeggmartinstri
germani
uml
roch
milano
itali
presenc
irradi
allogen
pbmc
sequenti
process
lymphocyt
cultur
day
complet
medium
contain
uml
wash
igg
lymphocyt
isol
deplet
igm
cell
highperform
cell
sorter
dakocytom
glostrup
denmark
cultur
complet
medium
ebvcontain
supernat
vv
h
wash
maintain
complet
medium
presenc
irradi
allogen
pbmc
number
viabl
lymphoblast
measur
microscop
trypan
blue
dye
exclus
indic
dna
intercal
fluoresc
dye
propidium
iodid
pi
sigma
aldritch
use
facscalibur
flow
cytomet
cellquest
softwar
becton
dickinson
franklin
lake
nj
assess
cell
viabil
viabl
cell
defin
high
forward
orthogon
scatter
characterist
lymphoblast
exclud
pi
express
measur
direct
immunofluoresc
briefli
cell
incub
min
antihuman
becton
dickinson
milano
itali
wash
fluoresc
analyz
use
facscalibur
flow
cytomet
cellquest
softwar
stain
evalu
viabl
lymphoblast
popul
gate
use
forwardorthagon
scatter
pi
stain
describ
background
stain
determin
fitcconjug
isotypematch
neg
control
mab
number
cell
analyz
microneutr
assay
adapt
previous
report
techniqu
briefli
helf
plate
onto
flatbottom
well
plate
minim
essenti
medium
mem
gibcobrl
milano
itali
fb
uml
penicillin
streptomycin
growth
medium
cultur
h
fifti
supernat
b
cell
clone
purifi
igg
indic
concentr
incub
laboratori
strain
hcmv
plaqu
form
unit
pfu
mem
fb
h
ad
fibroblast
monolay
plate
centrifug
g
min
incub
min
growth
medium
ad
cultur
incub
h
effect
b
cell
supernat
purifi
igg
hcmv
infect
measur
stain
hcmv
immedi
earli
antigen
iea
indirect
immunoperoxidas
ieaposit
nuclei
count
microscop
b
cell
supernat
contain
irrelev
igg
antibodi
use
neg
control
commerci
prepar
human
igg
purifi
serum
hcmv
seroposit
patient
cytotect
biotest
dreieich
germani
posit
control
respect
posit
defin
inhibit
iea
cell
compar
neg
control
well
hcmv
microneutr
assay
also
perform
endotheliotrop
hcmv
deriv
clinic
isol
recov
cervic
swab
pregnant
woman
huvec
describ
experi
perform
cell
passag
plaqu
reduct
assay
perform
report
select
experi
done
igg
purifi
protein
column
biorad
milano
italia
serumfre
supernat
natur
igg
antibodi
test
use
elisa
assay
detect
igg
bind
total
protein
extract
hcmv
virion
beia
cmv
igg
quant
kit
bouti
milano
itali
accord
manufactur
instruct
antihcmv
recombin
gb
igg
elisa
purchas
biotest
ag
dreieich
germani
use
accord
manufactur
instruct
elisa
make
use
recombin
autolog
interstrain
fusion
antigen
correspond
combin
gb
antigen
domain
hcmv
strain
swissprot
acc
town
swissprot
acc
region
contain
site
amino
acid
conserv
differ
viral
strain
shown
recogn
neutral
antibodi
gbgst
antigen
purchas
biodesign
saco
usa
contain
gb
immunodomin
region
fuse
gst
react
hcmvposit
sera
use
elisa
assay
accord
manufactur
instruct
antihcmv
recombin
ghspecif
elisa
perform
use
recombin
ghgst
antigen
coat
onto
plastic
ghgst
correspond
infram
fusion
gh
amino
termin
region
amino
acid
hcmv
strain
gst
amino
terminu
gh
contain
linear
antibodi
bind
site
residu
recogn
neutral
antibodi
gh
gene
segment
pcr
amplifi
dna
follow
primer
gh
f
gh
r
bp
pcr
product
digest
xhoi
bamhi
restrict
fragment
purifi
agaros
gel
elecrophoresi
clone
pgex
express
vector
amersham
restrict
xhoi
bamhi
gel
purifi
recombin
ghgst
fusion
protein
express
e
coli
purifi
bacteri
cell
lysat
basi
gst
affin
variabl
region
heavi
chain
vh
light
chain
vl
mab
sequenc
accord
technolog
establish
fusion
antibodi
ltd
briefli
frozen
cell
pellet
cell
use
extract
total
rna
rna
extract
reagent
cdna
produc
revers
transcript
oligo
primer
pcr
reaction
set
amplifi
vh
vl
region
mix
igg
specif
primer
respect
pcr
product
two
amplif
reaction
clone
use
eco
ri
restrict
site
sequenc
vector
invitrogen
use
transform
e
coli
cell
follow
manufactur
instruct
consensu
sequenc
determin
least
ten
clone
result
dna
sequenc
align
translat
protein
sequenc
enabl
gener
consensu
dna
protein
sequenc
vh
vl
vh
vl
protein
sequenc
compar
align
sequenc
present
genomequest
geneseq
ebi
databas
cdr
character
vh
vl
protein
sequenc
predict
imgt
databas
gener
recombin
consensu
vh
sequenc
amplifi
pcr
follow
primer
primer
contain
bglii
restrict
site
underlin
ligat
higg
express
vector
alreadi
contain
human
heavi
chain
constant
domain
inhous
design
bicistron
mammalian
retrovir
express
vector
pretmex
fusion
antibodi
ltd
belfast
ireland
dual
promot
vector
allow
express
antibodi
chain
vh
domain
clone
site
multipl
clone
site
mc
vector
complet
recombin
vector
confirm
dna
sequenc
cho
cell
adapt
serumfre
suspens
cultur
seed
cellsml
ml
spinner
flask
plasmid
dna
mix
linear
kda
pei
use
transfect
cell
cultur
medium
harvest
day
recombin
mab
purifi
protein
g
column
akta
prime
chromatographi
unit
follow
manufactur
standard
programm
recombin
igg
valu
express
mean
sd
data
analyz
signific
use
oneway
analysi
varianc
anova
bonferroni
posttest
correct
multipl
comparison
data
consid
signific
p
funaro
murphi
g
garotta
inventor
pct
patent
applic
publish
wo
describ
technolog
funaro
g
gribaudo
landolfo
inventor
unpublish
patent
applic
describ
specif
hcmvneutral
antibodi
isol
use
describ
technolog
patent
applic
file
name
ribovax
biotechnolog
sa
petitl
switzerland
data
analyz
signific
use
oneway
analysi
varianc
anova
bonferroni
posttest
correct
multipl
comparison
data
consid
signific
p
af
ggr
mm
gga
design
studi
al
carri
neutral
assay
nlb
carri
immunoassay
eo
particip
analysi
interpret
data
ev
lc
select
antibodi
neutral
sl
lf
contribut
design
studi
rb
prepar
recombin
igg
af
fm
wrote
paper
author
read
approv
final
manuscript
